In the past week, HCAT stock has gone down by -4.66%, with a monthly decline of -22.03% and a quarterly plunge of -30.39%. The volatility ratio for the week is 4.82%, and the volatility levels for the last 30 days are 6.59% for Health Catalyst Inc. The simple moving average for the past 20 days is -11.73% for HCAT’s stock, with a -22.71% simple moving average for the past 200 days.
Is It Worth Investing in Health Catalyst Inc (NASDAQ: HCAT) Right Now?
The 36-month beta value for HCAT is at 1.34. Analysts have varying views on the stock, with 8 analysts rating it as a “buy,” 2 rating it as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for HCAT is 58.54M, and currently, shorts hold a 4.38% of that float. The average trading volume for HCAT on January 31, 2025 was 630.18K shares.
HCAT) stock’s latest price update
The stock price of Health Catalyst Inc (NASDAQ: HCAT) has dropped by -1.95 compared to previous close of 5.63. Despite this, the company has seen a fall of -4.66% in its stock price over the last five trading days. globenewswire.com reported 2025-01-30 that SALT LAKE CITY, Jan. 30, 2025 (GLOBE NEWSWIRE) — Health Catalyst, Inc. (“Health Catalyst”, Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Dan Burton, Chief Executive Officer, Jason Alger, Chief Financial Officer, and Dan LeSueur, Chief Operating Officer, will participate in the BTIG at Snowbird: MedTech, Digital Health, Life Science & Diagnostic Tools Conference, in Snowbird, UT, on Tuesday, February 11, 2025.
Analysts’ Opinion of HCAT
Many brokerage firms have already submitted their reports for HCAT stocks, with KeyBanc Capital Markets repeating the rating for HCAT by listing it as a “Overweight.” The predicted price for HCAT in the upcoming period, according to KeyBanc Capital Markets is $9 based on the research report published on January 08, 2025 of the current year 2025.
Evercore ISI gave a rating of “Outperform” to HCAT, setting the target price at $11 in the report published on January 03rd of the previous year.
HCAT Trading at -23.30% from the 50-Day Moving Average
After a stumble in the market that brought HCAT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.31% of loss for the given period.
Volatility was left at 6.59%, however, over the last 30 days, the volatility rate increased by 4.82%, as shares sank -21.26% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -34.67% lower at present.
During the last 5 trading sessions, HCAT fell by -4.66%, which changed the moving average for the period of 200-days by -9.36% in comparison to the 20-day moving average, which settled at $6.25. In addition, Health Catalyst Inc saw -21.92% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HCAT starting from Llewelyn Linda, who sale 6,442 shares at the price of $5.80 back on Jan 15 ’25. After this action, Llewelyn Linda now owns 92,260 shares of Health Catalyst Inc, valued at $37,348 using the latest closing price.
LINDA LLEWELYN, the Officer of Health Catalyst Inc, proposed sale 6,442 shares at $5.90 during a trade that took place back on Jan 15 ’25, which means that LINDA LLEWELYN is holding shares at $38,008 based on the most recent closing price.
Stock Fundamentals for HCAT
Current profitability levels for the company are sitting at:
- -0.21 for the present operating margin
- 0.36 for the gross margin
The net margin for Health Catalyst Inc stands at -0.26. The total capital return value is set at -0.13. Equity return is now at value -21.46, with -10.37 for asset returns.
Based on Health Catalyst Inc (HCAT), the company’s capital structure generated 0.51 points at debt to capital in total, while cash flow to debt ratio is standing at -0.0. The debt to equity ratio resting at 1.03. The interest coverage ratio of the stock is -5.56.
Currently, EBITDA for the company is -68.28 million with net debt to EBITDA at -1.11. When we switch over and look at the enterprise to sales, we see a ratio of 1.23. The receivables turnover for the company is 5.85for trailing twelve months and the total asset turnover is 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.41.
Conclusion
In conclusion, Health Catalyst Inc (HCAT) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
